Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 74

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 74
---
 - | our limited operating history and experience in developing and manufacturing drugs; |

| - | none of our products are approved for commercial sale; |

| - | our substantial capital needs; |

| - | product development risks; |

| - | our lack of sales and marketing personnel; |

| - | regulatory, competitive and contractual risks; |

| - | no assurance that our product candidates will obtain regulatory approval or that the results of clinical 
 studies will be favorable;                                                                               |

| - | risks related to our intellectual property rights; |

| - | the volatility of the market price and trading volume in our Common Stock; |

| - | the risk that our Common Stock will be delisted from Nasdaq; |

| - | the absence of liquidity in our Common Stock; |

| - | the risk of substantial dilution from future issuances of our equity securities; and |

| - | the other risks set forth herein under the caption “Risk Factors.” |

<div align='center'>35</div>

The foregoing does not represent an exhaustive
list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. The factors
set forth above under “Risk Factors” and other cautionary statements made in this prospectus should be read and understood
as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements
contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance
on such statements. You should read this prospectus and the documents that we have filed as exhibits to this prospectus completely and
with the understanding that our actual future results may be materially different from the plans, intentions and expectations disclosed
in the forward-looking statements we make. Except as required by law, we undertake no obligation to update publicly any forward-looking
statements for any reason, even if new information becomes available or other events occur in the future. All subsequent written and oral
forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary
statements contained above and throughout this prospectus.

<div align='center'>36

Use of Proceeds</div>

We estimate that the net proceeds from this offering
will be approximately $13.5 million, or approximately $15.6 million if the underwriters exercise their over-allotment option in full,
based on an assumed public offering price of $10.30 per Unit, which was the closing price